Outcomes of liver transplantation patients infected with COVID-19: pandemic hospital experience from Turkey

Aims: There are conflicting results for the course of the disease and mortality rates for liver transplantation patients infected with COVID-19. In this study, we aimed to present the outcomes of our liver transplant patients who were hospitalized and followed up in our tertiary hospital, which served as a pandemic hospital for COVID-19. Methods: Patients hospitalized with the diagnosis of COVID-19 between March 1, 2020 and March 1, 2022 in Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital and Prof. Dr. Feriha Öz Pandemic Hospital were included. In this retrospective observational study, the clinical data of the patients, the need for intensive care hospitalization, and mortality rates were recorded by hospital computer system. The relationships were analyzed with SPSS v20.0. Results: There were 25996 patients who were hospitalized with the diagnosis of COVID-19 and 28 of them were with the history of liver transplantation. Ages of the liver transplant patients ranged from 18 to 73, with a median age of 52. 82.1% of the patients were male and 17.9% were female. Intensive care unit hospitalization rate was 25% and mortality rate was 14.3%. The relationships according to the age groups revealed that all of the women were under the age of 50 (p=0.008) and the patients who deceased were male patients over the age of 50 (p=0.044). Conclusion: Mortality rates and intensive care unit requirements of chronically immunosuppressed liver transplant patients with COVID-19 infection were similar with general population. Complete immunosuppression withdrawal should not be urged in this population.

Keywords:

COVID-19, infection, liver mortality, transplantation,

PDF

___

Amer FA, Saeed MA, Wagih Shaltout S, et al. Assessment and outcome of hospitalized patients during delta variant COVID-19 pandemic: a multicenter international study. J Infect Dev Ctries. 2022;16(11):1715-1725.
Yozgat A, Kasapoğlu B, Can G, et al. Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. Turk J Med Sci. 2021;51(3):1675-1681.
Kiyak M, Düzenli T. Lipase elevation on admission predicts worse clinical outcomes in patients with COVID-19. Pancreatology. 2022;22(5):665-670.
Güven BB, Özçelik F, Tanoglu A. Use of the derived isohemagglutinin parameter to predict patients with COVID-19 in need of an intensive care unit. Cent Eur J Immunol. 2022;47(1):73-83.
Düzenli T, Köseoğlu H. Endoscopic retrograde cholangiopancreatography during the COVID-19 pandemic: effects of enhanced personal protective equipment. Dig Dis Sci. 2021;66(6):1845-1851.
Eser F, Güner R, Gürbüz Y, et al. Impact of COVID-19 pandemic on diagnosis and treatment access of patients with viral hepatitis in Turkey. J Infect Dev Ctries. 2023;17(4):461-467.
Kabaçam G, Dayangaç M, Üçbilek E, et al. The COVID-19 pandemic: clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists. Turk J Gastroenterol. 2020;31(5):348-355.
Aydın O, Çolakoğlu MK, Öter V, et al. COVID-19 infection frequency and clinical course in patients with liver transplantation: results of a single transplant center in Türkiye. Turk J Surg. 2022;38(3):283-288.
Khazaaleh S, Alomari M, Sharma S, Kapila N, Zervos XB, Gonzalez AJ. COVID-19 in liver transplant patients: impact and considerations. World J Transplant. 2023;13(1):1-9.
Yavuz Y, Durgut H. Evaluation of 846 liver transplant patients infected with COVID-19 in Turkey. Med J Bakirkoy. 2022;18:225-229.
Canbaz H, Beştemir A, Surel AA, ve ark. Türkiye‘de covıd-19 ile enfekte olan solid organ nakilli hastaların acil servis ve hastane başvurularının incelenmesi. Tıbbi Sosyal Hizmet Derg. 2021;18:66-81.
Kulkarni AV, Tevethia HV, Premkumar M, et al. Impact of COVID-19 on liver transplant recipients-a systematic review and meta-analysis. EClinicalMedicine. 2021;38:101025.
Moon AM, Webb GJ, García-Juárez I, et al. SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination. Hepatol Commun. 2022;6(4):889-897.
Yuksel M, Akturk H, Mizikoglu O, Toroslu E, Arikan C. A single-center report of COVID-19 disease course and management in liver transplanted pediatric patients. Pediatr Transplant. 2021;25(7):e14061.
Siddiqui MA, Bakirci O, Dönger U, Warasnhe K, Özçay F, Haberal M. Clinical features and outcomes following SARS-CoV-2 infection in pediatric liver transplant patients. Exp Clin Transplant. 2022;20(Suppl 3):66-71.
Akbulut S, Yagin FH, Sahin TT, et al. Effect of COVID-19 pandemic on patients who have undergone liver transplantation: retrospective cohort study. J Clin Med. 2023;12(13):4466.
Gkoufa A, Saridaki M, Georgakopoulou VE, Spandidos DA, Cholongitas E. COVID‑19 vaccination in liver transplant recipients. Exp Ther Med. 2023;25(6):291.
Colmenero J, Rodríguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74(1):148-155.
Bhoori S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020;5(6):532-533.
Webb GJ, Moon AM, Barnes E, Barritt AS, Marjot T. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol. 2020;5(7):643-644.
Eren-Kutsoylu OO, Egeli T, Agalar C, et al. COVID-19 in liver transplant patients: a university hospital experience. Transplant Proc. 2023;55(5):1223-1225.
Parente A, Manzia TM, Angelico R, et al. COVID-19, liver transplant, and immunosuppression: allies or foes?. Transpl Infect Dis. 2021;23(1):e13417.
Belli LS, Fondevila C, Cortesi PA, et al. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with COVID-19: results from the ELITA/ELTR multi-center European study. Gastroenterology. 2021;160(4):1151-1163.e3.